Display options
Cite
Lim SY, Bauermeister A, Kjonaas RA, et al. Phytol-based novel adjuvants in vaccine formulation: 2. Assessment of efficacy in the induction of protective immune responses to lethal bacterial infections in mice. J Immune Based Ther Vaccines. 2006;4:5doi: 10.1186/1476-8518-4-5.
Lim, S. Y., Bauermeister, A., Kjonaas, R. A., & Ghosh, S. K. (2006). Phytol-based novel adjuvants in vaccine formulation: 2. Assessment of efficacy in the induction of protective immune responses to lethal bacterial infections in mice. Journal of immune based therapies and vaccines, 45. https://doi.org/10.1186/1476-8518-4-5
Lim, So-Yon, et al. "Phytol-based novel adjuvants in vaccine formulation: 2. Assessment of efficacy in the induction of protective immune responses to lethal bacterial infections in mice." Journal of immune based therapies and vaccines vol. 4 (2006): 5. doi: https://doi.org/10.1186/1476-8518-4-5
Lim SY, Bauermeister A, Kjonaas RA, Ghosh SK. Phytol-based novel adjuvants in vaccine formulation: 2. Assessment of efficacy in the induction of protective immune responses to lethal bacterial infections in mice. J Immune Based Ther Vaccines. 2006 Oct 23;4:5. doi: 10.1186/1476-8518-4-5. PMID: 17059608; PMCID: PMC1633728.
Copy Download .nbib Format: NLM
Share it on

J Immune Based Ther Vaccines. 2006 Oct 23;4:5. doi: 10.1186/1476-8518-4-5.

Phytol-based novel adjuvants in vaccine formulation: 2. Assessment of efficacy in the induction of protective immune responses to lethal bacterial infections in mice.

Journal of immune based therapies and vaccines

So-Yon Lim, Adam Bauermeister, Richard A Kjonaas, Swapan K Ghosh

Affiliations

  1. Department of Life Sciences, Indiana State University, Terre Haute, IN 47809, USA. [email protected]

PMID: 17059608 PMCID: PMC1633728 DOI: 10.1186/1476-8518-4-5

Abstract

BACKGROUND: Adjuvants are known to significantly enhance vaccine efficacy. However, commercial adjuvants often have limited use because of toxicity in humans. The objective of this study was to determine the comparative effectiveness of a diterpene alcohol, phytol and its hydrogenated derivative PHIS-01, relative to incomplete Freund's adjuvant (IFA), a commonly used adjuvant in augmenting protective immunity in mice against E. coli and S. aureus, and in terms of inflammatory cytokines.

METHODS: Vaccines, consisting of heat-attenuated E. coli or S. aureus and either of the two phytol-based adjuvants or IFA, were tested in female BALB/c mice. The vaccines were administered intraperitoneally at 10-day intervals. The efficacy of the phytol and PHIS-01, as compared to IFA, was assessed by ELISA in terms of anti-bacterial antibody and inflammatory cytokines. We also examined the ability of the vaccines to induce specific protective immunity by challenging mice with different doses of live bacteria.

RESULTS AND DISCUSSION: IFA, phytol, and PHIS-01 were equally efficient in evoking anti-E. coli antibody response and in providing protective immunity against live E. coli challenges. In contrast, the antibody response to S. aureus was significant when PHIS-01 was used as the adjuvant. However, in terms of the ability to induce protective immunity, phytol was most effective against S. aureus. Moreover, during challenges with live E. coli and S. aureus immune mice produced much less IL-6, the mediators of fatal septic shock syndromes.

CONCLUSION: Our results show that vaccine formulations containing phytol and PHIS-01 as adjuvants confer a robust and protective immunity against both Gram-negative and Gram-positive bacteria without inducing adverse inflammatory cytokine due to IL-6.

References

  1. Nat Immunol. 2004 Oct;5(10):971-4 - PubMed
  2. Infect Immun. 2003 Dec;71(12):6864-70 - PubMed
  3. Immunol Cell Biol. 2004 Oct;82(5):488-96 - PubMed
  4. Annu Rev Immunol. 2002;20:197-216 - PubMed
  5. Annu Rev Immunol. 2003;21:335-76 - PubMed
  6. Infect Immun. 1993 Mar;61(3):975-80 - PubMed
  7. Nature. 1987 Dec 17-23;330(6149):662-4 - PubMed
  8. Infect Immun. 1996 Aug;64(8):3231-5 - PubMed
  9. Infect Immun. 1996 Apr;64(4):1369-72 - PubMed
  10. J Immunol Methods. 1992 Aug 30;153(1-2):67-71 - PubMed
  11. J Immunol. 1992 Jan 1;148(1):234-8 - PubMed
  12. Infect Immun. 1977 Aug;17(2):286-9 - PubMed
  13. Urologe A. 2003 Jan;42(1):13-25 - PubMed
  14. J Immunol. 1997 Jul 15;159(2):970-5 - PubMed
  15. J Exp Med. 2002 Mar 4;195(5):F19-23 - PubMed
  16. Nurs Clin North Am. 1999 Jun;34(2):427-42 - PubMed
  17. J Clin Invest. 2004 Aug;114(4):450-62 - PubMed
  18. Infect Immun. 2004 Sep;72(9):5247-52 - PubMed
  19. J Immune Based Ther Vaccines. 2006 Oct 30;4:6 - PubMed
  20. Scand J Immunol. 2004 Jan;59(1):34-9 - PubMed
  21. Infect Immun. 1995 Apr;63(4):1165-72 - PubMed
  22. Infect Immun. 2000 May;68(5):2424-30 - PubMed
  23. Infect Immun. 2000 Jan;68(1):125-32 - PubMed
  24. Infect Immun. 1998 Jul;66(7):3270-8 - PubMed
  25. Infect Immun. 2001 Aug;69(8):4969-79 - PubMed
  26. Infect Immun. 2002 Aug;70(8):4254-60 - PubMed

Publication Types